- Home
- Companies
- 2A Pharma ApS
- Products
- 2A Pharma - Model 2AP01 - HPV Vaccine
2A Pharma - Model 2AP01 - HPV Vaccine
The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults too.
More than 170 types of Human Papillomavirus have been fully sequenced and there are many more to be investigated. The most advanced approved HPV vaccine provides protection against nine HPV types. In pre-clinical tests, 2A Pharma’s HPV vaccine candidate, formulated without adjuvant, has been shown to provide protection against more than 20 HPV types (and we are still testing), including several that can cause both mucosal and cutaneous cancers in which existing vaccines do not protect against.
- Broader coverage than approved HPV vaccines
- Formulated without adjuvants
- Low production cost
- First-in-human, clinical phase 1 trial finished